Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667

Category Primary study
JournalKlinische Padiatrie
Year 2020
This article has no abstract
Epistemonikos ID: 3ae10ad2889efc364adf2f00fed23c593a2b91c3
First added on: Feb 11, 2025